Intellipharmaceutics International (NASDAQ: IPCI) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Volatility & Risk

Intellipharmaceutics International has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Dividends

Johnson & Johnson pays an annual dividend of $3.36 per share and has a dividend yield of 2.5%. Intellipharmaceutics International does not pay a dividend. Johnson & Johnson pays out 56.8% of its earnings in the form of a dividend. Intellipharmaceutics International has increased its dividend for 54 consecutive years.

Profitability

This table compares Intellipharmaceutics International and Johnson & Johnson’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intellipharmaceutics International -225.15% -867.02% -135.20%
Johnson & Johnson 22.52% 26.76% 13.19%

Earnings and Valuation

This table compares Intellipharmaceutics International and Johnson & Johnson’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Intellipharmaceutics International $4.36 million 7.78 -$9.05 million ($0.34) -3.26
Johnson & Johnson $72.53 billion 4.93 $25.15 billion $5.92 22.50

Johnson & Johnson has higher revenue and earnings than Intellipharmaceutics International. Intellipharmaceutics International is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Intellipharmaceutics International and Johnson & Johnson, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellipharmaceutics International 0 2 2 0 2.50
Johnson & Johnson 4 8 7 0 2.16

Intellipharmaceutics International currently has a consensus target price of $3.78, suggesting a potential upside of 240.09%. Johnson & Johnson has a consensus target price of $133.56, suggesting a potential upside of 0.27%. Given Intellipharmaceutics International’s stronger consensus rating and higher probable upside, equities analysts plainly believe Intellipharmaceutics International is more favorable than Johnson & Johnson.

Institutional & Insider Ownership

4.2% of Intellipharmaceutics International shares are held by institutional investors. Comparatively, 65.9% of Johnson & Johnson shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Intellipharmaceutics International on 10 of the 16 factors compared between the two stocks.

About Intellipharmaceutics International

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive News & Stock Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related stocks with our FREE daily email newsletter.